U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07418879) titled 'A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC' on Feb. 03.
Brief Summary: This study is a single-arm, multicenter real-world clinical study designed to evaluate the safety and efficacy of Leucogen (a leukocyte-increasing agent) as a prophylactic treatment in patients with RET fusion-positive non-small cell lung cancer (NSCLC) who are being treated with Pralsetinib.
Study Start Date: Feb. 05
Study Type: INTERVENTIONAL
Condition:
Non-small Cell Lung Cancer
RET Fusion
Pralsetinib
Intervention:
DRUG: Pralsetinib
Pralsetinib 400mg orally once daily on an empty stomach (4 wee...